GB8531071D0
(en)
*
|
1985-12-17 |
1986-01-29 |
Boots Co Plc |
Therapeutic compound
|
WO1994000114A1
(fr)
*
|
1992-06-23 |
1994-01-06 |
Sepracor Inc. |
Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure
|
AU721924B2
(en)
*
|
1992-06-23 |
2000-07-20 |
Sepracor, Inc. |
Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
|
GB9301192D0
(en)
|
1993-06-09 |
1993-06-09 |
Trott Francis W |
Flower shaped mechanised table
|
US5459164A
(en)
*
|
1994-02-03 |
1995-10-17 |
Boots Pharmaceuticals, Inc. |
Medical treatment
|
DE19518988A1
(de)
*
|
1995-05-29 |
1996-12-05 |
Basf Ag |
Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
|
GB9619757D0
(en)
|
1996-09-21 |
1996-11-06 |
Knoll Ag |
Chemical process
|
GB9619962D0
(en)
*
|
1996-09-25 |
1996-11-13 |
Knoll Ag |
Medical treatment
|
GB9619961D0
(en)
*
|
1996-09-25 |
1996-11-13 |
Knoll Ag |
Medical treatment
|
GB9727131D0
(en)
|
1997-12-24 |
1998-02-25 |
Knoll Ag |
Therapeutic agents
|
US6331571B1
(en)
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
US6974838B2
(en)
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
US6476078B2
(en)
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
US6046242A
(en)
*
|
1998-11-27 |
2000-04-04 |
Basf Aktiengesellschaft |
Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
|
US6696495B2
(en)
|
1998-12-02 |
2004-02-24 |
Snowden Pharmaceuticals, Llc |
Treatment of disorders secondary to organic impairments
|
US6323242B1
(en)
|
1998-12-02 |
2001-11-27 |
Peter Sterling Mueller |
Treatment of disorders secondary to organic impairments
|
BG65170B1
(bg)
*
|
1999-03-17 |
2007-05-31 |
Knoll Gmbh |
Използване на n-заместени производни на 1-[1-(4-хлорофенил)циклобутил]-3-метилбутиламин за производство на лекарство за лечение на разстройства при храненето
|
MXPA01009467A
(es)
*
|
1999-03-19 |
2004-03-19 |
Knoll Gmbh |
Metodo para controlar el aumento de peso asociado con farmacos terapeuticos.
|
US6803387B1
(en)
*
|
1999-03-19 |
2004-10-12 |
Abbott Gmbh & Co. Kg |
Treatment of neuropathic pain or fibromyalgia
|
JP2002539252A
(ja)
*
|
1999-03-19 |
2002-11-19 |
クノール・ゲー・エム・ベー・ハー |
胆石の治療
|
CA2367268A1
(fr)
*
|
1999-03-19 |
2000-09-28 |
Knoll Pharmaceutical Company |
Perte de poids apres une grossesse
|
AU3894600A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Pharmaceutical Company |
Method of treating sexual dysfunction
|
WO2000056312A1
(fr)
|
1999-03-19 |
2000-09-28 |
Knoll Gmbh |
Traitement de l'hypertension arterielle pulmonaire
|
ES2244420T3
(es)
*
|
1999-03-19 |
2005-12-16 |
ABBOTT GMBH & CO. KG |
Utilizacion de la sibutramina o de uno de sus derivados para el tratamiento de los trastornos del sueño.
|
NZ514016A
(en)
*
|
1999-03-19 |
2001-09-28 |
Knoll Gmbh |
Treatment of osteoarthritis
|
AU773188C
(en)
*
|
1999-03-19 |
2006-01-05 |
Abbott Gmbh & Co. Kg |
Method of treating eating disorders
|
US6552087B1
(en)
|
1999-03-19 |
2003-04-22 |
Abbott Gmbh & Co. Kg |
Therapeutic agent comprising (+)-sibutramine
|
AU3895300A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Pharmaceutical Company |
Treatment of chronic fatigue syndrome
|
WO2000056311A1
(fr)
*
|
1999-03-19 |
2000-09-28 |
Knoll Pharmaceutical Company |
Regulation du metabolisme
|
AU3899100A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Pharmaceutical Company |
Treatment of hyperactivity disorders
|
WO2000056308A1
(fr)
|
1999-03-19 |
2000-09-28 |
Knoll Pharmaceutical Company |
Prevention de maladies cardio-vasculaires
|
US6365632B1
(en)
|
1999-03-19 |
2002-04-02 |
Knoll Pharmaceuticals Company |
Treatment of orthostatic hypotension
|
US6245782B1
(en)
|
1999-05-17 |
2001-06-12 |
Heartdrug Research L.L.C. |
Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
GB9926251D0
(en)
*
|
1999-11-06 |
2000-01-12 |
Knoll Ag |
Pharmaceutical formulation
|
GB0004003D0
(en)
*
|
2000-02-22 |
2000-04-12 |
Knoll Ag |
Therapeutic agents
|
AU2001282913A1
(en)
*
|
2000-09-08 |
2002-03-22 |
Eli Lilly And Company |
A method of treating weight gain associated with atypical antipsychotic use
|
FR2814678B1
(fr)
†
|
2000-10-04 |
2002-12-20 |
Aventis Pharma Sa |
Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
WO2002083631A1
(fr)
*
|
2001-04-13 |
2002-10-24 |
Sepracor Inc. |
Procedes permettant la preparation de didesmethylsibutramine et d'autres derives de sibutramine
|
US20030139386A1
(en)
*
|
2001-12-21 |
2003-07-24 |
Sophie Cote |
Pharmaceutical compositions based on azetidine derivatives
|
NZ534757A
(en)
*
|
2002-03-12 |
2006-07-28 |
Merck & Co Inc |
Substituted amides
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
US20040122033A1
(en)
*
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US20050131074A1
(en)
*
|
2003-08-04 |
2005-06-16 |
Beckman Kristen M. |
Methods for treating metabolic syndrome
|
WO2005028438A1
(fr)
|
2003-09-22 |
2005-03-31 |
Banyu Pharmaceutical Co., Ltd. |
Nouveau derive de piperidine
|
EP2305352A1
(fr)
|
2004-04-02 |
2011-04-06 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques
|
US7432398B2
(en)
|
2005-01-06 |
2008-10-07 |
Cj Corporation |
Inorganic acid salts of sibutramine
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
ES2574014T3
(es)
|
2005-05-30 |
2016-06-14 |
Msd K.K. |
Derivado de piperidina novedoso
|
EP1916239A4
(fr)
|
2005-08-10 |
2009-10-21 |
Banyu Pharma Co Ltd |
Composé de pyridone
|
EP1921065B1
(fr)
|
2005-08-24 |
2010-10-20 |
Banyu Pharmaceutical Co., Ltd. |
Dérivé phénylpyridone
|
WO2007029847A1
(fr)
|
2005-09-07 |
2007-03-15 |
Banyu Pharmaceutical Co., Ltd. |
Dérivé de pyridone substitué aromatique bicylique
|
WO2007034910A1
(fr)
*
|
2005-09-22 |
2007-03-29 |
Eisai R & D Management Co., Ltd. |
Préparation thérapeutique pour le traitement de la boulimie et de la dépression associée à la boulimie
|
EP1940842B1
(fr)
|
2005-09-29 |
2012-05-30 |
Merck Sharp & Dohme Corp. |
Dérivés acylés de spiropipéridine en tant que modulateurs du récepteur de la mélanocortine-4
|
US8911751B2
(en)
*
|
2005-10-11 |
2014-12-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Compositions for nasal delivery
|
BRPI0617621A2
(pt)
|
2005-10-21 |
2011-08-02 |
Novartis Ag |
combinação de compostos orgánicos
|
AU2006307046A1
(en)
|
2005-10-27 |
2007-05-03 |
Msd K.K. |
Novel benzoxathiin derivative
|
MY146564A
(en)
|
2005-11-10 |
2012-08-30 |
Msd Kk |
Aza-substituted spiro derivatives
|
RU2455981C2
(ru)
*
|
2006-06-16 |
2012-07-20 |
Теракос, Инк. |
Лечение ожирения антагонистами мускаринового рецептора м1
|
US8748419B2
(en)
|
2006-06-16 |
2014-06-10 |
Theracos, Inc. |
Treating obesity with muscarinic receptor M1 antagonists
|
MX2009002282A
(es)
|
2006-09-07 |
2009-03-20 |
Nycomed Gmbh |
Tratamiento de combinacion para diabetes mellitius.
|
EP2066329B1
(fr)
*
|
2006-09-15 |
2017-09-06 |
Reviva Pharmaceuticals, Inc. |
Synthèse, utilisation et compositions de cyclobutylméthylamines
|
US8604244B2
(en)
|
2010-07-02 |
2013-12-10 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
|
EP2698157B1
(fr)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
|
WO2008038692A1
(fr)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
dÉrivÉ de diarylcÉtimine
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
CN101795684A
(zh)
*
|
2007-04-09 |
2010-08-04 |
赛多斯有限责任公司 |
他汀类化合物与抗肥胖药的组合
|
CA2963857A1
(fr)
|
2007-06-04 |
2008-12-11 |
Ben-Gurion University Of The Negev Research And Development Authority |
Composes triaryles et compositions les comprenant
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
CA2714617A1
(fr)
|
2008-03-06 |
2009-09-11 |
Banyu Pharmaceutical Co., Ltd. |
Derive d'alkylaminopyridine
|
US20110015198A1
(en)
|
2008-03-28 |
2011-01-20 |
Banyu Pharmaceutical Co., Inc. |
Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
|
EP3239170B1
(fr)
|
2008-06-04 |
2019-03-20 |
Synergy Pharmaceuticals Inc. |
Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
|
EP2301936A1
(fr)
|
2008-06-19 |
2011-03-30 |
Banyu Pharmaceutical Co., Ltd. |
Dérivé de spirodiamine-diarylcétoxime
|
EP3241839B1
(fr)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
|
EP2319841A1
(fr)
|
2008-07-30 |
2011-05-11 |
Msd K.K. |
Dérivé de cycloalkylamine à noyaux fusionnés à (5 chaînons)-(5 chaînons) ou (5 chaînons) (6 chaînons)
|
CA2741125A1
(fr)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Nouveaux derives de benzimidazole cycliques utiles comme agents anti-diabetiques
|
WO2010051206A1
(fr)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques
|
WO2010065889A2
(fr)
*
|
2008-12-06 |
2010-06-10 |
Auspex Pharmaceutical |
Inhibiteurs cyclobutaneméthanamine de la réabsorption de monoamine
|
US20110243940A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Bicyclic pyranone derivatives and methods of use thereof
|
EP2379547A1
(fr)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Dérivés de pyridopyrimidine et leurs procédés d'utilisation
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
EP2677869B1
(fr)
|
2011-02-25 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
|
AU2013296470B2
(en)
|
2012-08-02 |
2016-03-17 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
AU2014219020A1
(en)
|
2013-02-22 |
2015-07-23 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2014139388A1
(fr)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
CA2905435A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions utiles pour le traitement de troubles gastro-intestinaux
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
|
WO2015051496A1
(fr)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Composés tricycliques antidiabétiques
|
JP6657101B2
(ja)
|
2013-11-05 |
2020-03-04 |
ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ |
糖尿病及びそれから生じる疾患合併症の治療のための化合物
|
JP6769963B2
(ja)
|
2014-08-29 |
2020-10-14 |
ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ |
α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤
|
AU2017342083A1
(en)
|
2016-10-14 |
2019-04-11 |
Tes Pharma S.R.L. |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
|
EP3551176A4
(fr)
|
2016-12-06 |
2020-06-24 |
Merck Sharp & Dohme Corp. |
Composés hétérocycliques antidiabétiques
|
EP3558298A4
(fr)
|
2016-12-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
Composés de spirochromane antidiabétiques
|
KR20210111248A
(ko)
|
2018-11-20 |
2021-09-10 |
테스 파마 에스.알.엘. |
α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제
|